Search

Your search keyword '"Donadio, M"' showing total 336 results

Search Constraints

Start Over You searched for: Author "Donadio, M" Remove constraint Author: "Donadio, M"
336 results on '"Donadio, M"'

Search Results

1. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2. Ab-initio simulation of photoinduced transformation of small rings in amorphous silica

3. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

7. C25 - Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

8. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

10. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

11. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

18. P-54 BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal

20. P-55 GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells

21. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

22. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

27. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

33. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

34. Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study

36. Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial

37. Abstract GS3-01: A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

38. Abstract P4-13-04: Not presented

39. 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

40. Abstract P1-13-02: Withdrawn

41. Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial

42. Effect of Intra- and Extrauterine Growth on Long-Term Neurologic Outcomes of Very Preterm Infants

43. Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM)

44. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

45. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study

46. From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial

47. Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

48. Nab-paclitaxel in clinical practice: data from the MANTEL study

49. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study

50. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study

Catalog

Books, media, physical & digital resources